Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).

被引：7

作者：

Knox, Jennifer J.

Barrios, Carlos H.

Kim, Tae Min

Cosgriff, Thomas

Srimuninnimit, Vichien

Pittman, Kenneth B.

Sabbatini, Roberto

Rha, Sun Young

Flaig, Thomas W.

Page, Ray D.

Beck, J. Thaddeus

Cheung, Foon Yiu

Yadav, Sunil

Patel, Poulam M.

Geoffrois, Lionnel

Schiff, Edward

Niolat, Julie

Berkowitz, Noah

Voi, Maurizio

Motzer, Robert

机构：

[1] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[2] PUCRS Sch Med, Porto Alegre, RS, Brazil

[3] Seoul Natl Univ Hosp, Jongno Gu, South Korea

[4] East Jefferson Gen Hosp, Crescent City Res Consortium, Metairie, LA USA

[5] Siriraj Hosp, Bangkok, Thailand

[6] Queen Elizabeth Hosp, Woodville, SA 5011, Australia

[7] AOU Policlin Modena, Modena, Italy

[8] Yonsei Univ Coll Med, Seoul, South Korea

[9] Univ Colorado Canc Ctr, Aurora, CO USA

[10] Ctr Canc & Blood Disorders, Ft Worth, TX USA

[11] Highlands Oncol Grp, Fayetteville, AR USA

[12] Queen Elizabeth Hosp, Kowloon, Hong Kong, Peoples R China

[13] Univ Saskatchewan, Saskatoon Canc Ctr, Saskatoon, SK, Canada

[14] Univ Nottingham, Nottingham NG7 2RD, England

[15] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France

[16] Novartis Pharmaceut, E Hanover, NJ USA

[17] Novartis Pharma SAS, Rueil Malmaison, France

[18] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.4554

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4554

引用

页数：1

共 50 条

[31] Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma
Wells, J. Connor
Graham, Jeffrey
Beuselinck, Benoit
Bjarnason, Georg A.
Donskov, Frede
Hansen, Aaron R.
McKay, Rana R.
Vaishampayan, Ulka
De Velasco, Guillermo
Duh, Mei S.
Huynh, Lynn
Nguyen, Catherine
Zanotti, Giovanni
Ramaswamy, Krishnan
Choueiri, Toni K.
Heng, Daniel Y. C.
[J]. CLINICAL GENITOURINARY CANCER, 2020, 18 (04) : E350 - E359
[32] FINAL QUALITY OF LIFE (QOL) RESULTS WITH GEOGRAPHICAL ANALYSIS FOR SUNITINIB VERSUS INTERFERON-ALFA, AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
Cella, D.
Michaelson, M. D.
Bushmakin, A. G.
Cappelleri, J. C.
Charbonneau, C.
Kim, S. T.
Li, J. Z.
Motzer, R. J.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A283 - A283
[33] The effect of age on first-line sunitinib treatment in patients with renal cell carcinoma (RCC).
Coward, J. I. G.
Larbi, E. D.
Pandha, H. S.
Michael, A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[34] Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Motzer, Robert J.
Porta, Camillo
Eto, Masatoshi
Powles, Thomas
Gruenwald, Viktor
Hutson, Thomas E.
Alekseev, Boris
Rha, Sun Young
Merchan, Jaime
Goh, Jeffrey C.
Lalani, Aly-Khan A.
De Giorgi, Ugo
Melichar, Bohuslav
Hong, Sung-Hoo
Gurney, Howard
Mendez-Vidal, Maria Jose
Kopyltsov, Evgeny
Tjulandin, Sergei
Gordoa, Teresa Alonso
Kozlov, Vadim
Alyasova, Anna
Winquist, Eric
Maroto, Pablo
Kim, Miso
Peer, Avivit
Procopio, Giuseppe
Takagi, Toshio
Wong, Shirley
Bedke, Jens
Schmidinger, Manuela
Rodriguez-Lopez, Karla
Burgents, Joseph
He, Cixin
Okpara, Chinyere E.
Mckenzie, Jodi
Choueiri, Toni K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11)
[35] Impact of dose reduction on survival in patients starting sunitinib (SU) or pazopanib (PA) as first-line for metastatic renal cell carcinoma (mRCC).
Iacovelli, Roberto
Derosa, Lisa
Massari, Francesco
Verri, Elena
Galli, Luca
Ciccarese, Chiara
Rocca, Maria Cossu
Cianci, Claudia
Bimbatti, Davide
Aurilio, Gaetano
Antonuzzo, Andrea
Fantinel, Emanuela
Cullura, Daniela
Ricci, Sergio
Modena, Alessandra
Falcone, Alfredo
Tortora, Giampaolo
Nole, Franco
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
[36] Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects
Vuorinen, Riikka-Liisa
Paunu, Niina
Turpeenniemi-Hujanen, Taina
Reunamo, Taina
Jekunen, Antti
Kataja, Vesa
Sintonen, Harri
Purmonen, Timo
Kellokumpu-Lehtinen, Pirkko-Liisa
[J]. ANTICANCER RESEARCH, 2019, 39 (10) : 5559 - 5564
[37] First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience
Lalani, Aly-Khan A.
Li, Haocheng
Heng, Daniel Y. C.
Wood, Lori
Kalirai, Austin
Bjarnason, Georg A.
Sim, Hao-Wen
Kollmannsberger, Christian K.
Kapoor, Anil
Hotte, Sebastien J.
Vanhuyse, Marie
Czaykowski, Piotr
Reaume, M. Neil
Soulieres, Denis
Venner, Peter
North, Scott
Basappa, Naveen S.
[J]. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (3-4): : 112 - 117
[38] Characterizing prior nephrectomy patients with metastatic renal cell carcinoma (mRCC) treated with first-line sunitinib versus interferon-alfa
Figlin, R. A.
Hutson, T. E.
Tomczak, P.
Michaelson, M. D.
Bjarnason, G. A.
Lin, X.
Lowenthal, S. Pitman
Korytowsky, B.
Matczak, E.
Oudard, S.
[J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S644 - S645
[39] Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)
Rodriguez-Vida, Alejo
Bamias, Aristotelis
Esteban, Emilio
Isabel Saez, Maria
Lopez-Brea, Marta
Castellano, Daniel
Caballero, Cristina
Luis Gonzalez-Larriba, Jose
Calvo, Emiliano
Macia, Sonia
Ravaud, Alain
Bellmunt, Joaquim
[J]. BJU INTERNATIONAL, 2020, 126 (05) : 559 - 567
[40] Axitinib versus sunitinib as first-line therapies for metastatic renal cell carcinoma: A multicenter retrospective analysis.
Hatakeyama, Shingo
Tanaka, Toshiaki
Ikehata, Yoshinori
Fujita, Naoki
Masumori, Naoya
Kitamura, Hiroshi
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Ohyama, Chikara
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)

← 1 2 3 4 5 →